Literature DB >> 33987227

CHI3L1 alleviate acute liver injury by inhibiting Th1 cells differentiation through STAT3 signaling pathway.

Shaopeng Zhang1, Xinzheng Dai1, Yong Shi1, Xiaowen Zhu1, Yongjiu Dai1, Xiaofeng Qian1, Jian Gu1.   

Abstract

BACKGROUND: Acute liver injury (ALI) is a severe liver disease. Chitinase 3-like-1 (CHI3L1), a protein belonging to the glycosyl hydrolase family 18, is involved in many diseases, such as inflammatory diseases, bacterial infections, and various malignant tumors; however, the function of CHI3L1 in ALI remains unclear. The objective of this study was to evaluate the protective functions of CHI3L1 against thioacetamide (TAA)-induced ALI in mice and explore its potential mechanisms.
METHODS: Data from 20 patients with ALI and 10 healthy subjects was collected. Serum CHI3L1, serum aspartate transaminase (AST), and serum alanine aminotransferase (ALT) were measured. To establish ALI mouse models, thioacetamide was intraperitoneally injected into groups of the CHI3L1-knockout (CHI3L1-KO) and wild-type (WT) mice (80 and 150 mg/kg). Recombinant CHI3L1 protein (rCHI3L1) (5 µg/kg), IFN-γ (500 ng), and WP1033 (an inhibitor of P-STAT3, 0.2 mL) were injected before TAA treatment, after which the effects were estimated. Splenic CD4+CD62L+ naive T cells were isolated from CHI3L1-KO mice and stimulated to differentiate into regulatory T (Treg) cells, T-helper 1 (Th1) cells, T-helper 2 (Th2) cells, and T-helper 17 (Th17) cells.
RESULTS: Increased serum CHI3L1 levels were seen both in healthy subjects and post-therapy patients compared with ALI patients. CHI3L1 levels were negatively correlated with serum ALT and AST levels in ALI patients. CHI3L1-KO group showed higher serum ALT and AST levels than the WT group following TAA treatment, while tail vein injection of rCHI3L1 reduced liver tissue injury and improved Treg cell differentiation in vivo. In vitro experiment showed that knockout of CHI3L1 improved IFN-γ+ Th1 cell differentiation. Furthermore, intraperitoneal administration of IFN-γ produced more severe hepatocellular necrosis compared with rCHI3L1 injection alone. Mechanism study showed that T-box expressed in T cells (T-bet), and signal transducer and activator of transcription 3 (STAT3), play a critical role in adversely mediating the effect of CHI3L1, which is consistent with the finding that treatment with WP1033 down-regulated the differentiation of the Th1 cells in vitro and reduced severity of liver injury in vivo.
CONCLUSIONS: CHI3L1 reduced the production of IFN-γ and inhibited Th1 cell differentiation through the STAT3 signaling pathway, which could be a potential therapeutic strategy for treating ALI. 2021 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Acute liver injury (ALI); Th1 cell; chitinase 3-like-1 (CHI3L1); signal transducer and activator of transcription 3 (STAT3)

Year:  2021        PMID: 33987227      PMCID: PMC8105831          DOI: 10.21037/atm-20-6127

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  30 in total

1.  CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells.

Authors:  Bo Mi Ku; Yeon Kyung Lee; Jinhyun Ryu; Joo Yeon Jeong; Jungil Choi; Keyoung Mi Eun; Hye Young Shin; Dong Gyu Kim; Eun Mi Hwang; Jae Cheal Yoo; Jae-Yong Park; Gu Seob Roh; Hyun Joon Kim; Gyeong Jae Cho; Wan Sung Choi; Sun Ha Paek; Sang Soo Kang
Journal:  Int J Cancer       Date:  2011-03-15       Impact factor: 7.396

2.  Chitinase-3-like-1 deficiency attenuates ethanol-induced liver injury by inhibition of sterol regulatory element binding protein 1-dependent triglyceride synthesis.

Authors:  Dong Hun Lee; Ji Hye Han; Yong Sun Lee; Young Suk Jung; Yoon Seok Roh; Jae Suk Yun; Sang Bae Han; Jin Tae Hong
Journal:  Metabolism       Date:  2019-03-29       Impact factor: 8.694

Review 3.  Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury.

Authors:  Chun Geun Lee; Carla A Da Silva; Charles S Dela Cruz; Farida Ahangari; Bing Ma; Min-Jong Kang; Chuan-Hua He; Seyedtaghi Takyar; Jack A Elias
Journal:  Annu Rev Physiol       Date:  2011       Impact factor: 19.318

4.  CD4(+) T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver.

Authors:  R M Zwacka; Y Zhang; J Halldorson; H Schlossberg; L Dudus; J F Engelhardt
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

Review 5.  Role of oxidative stress and molecular changes in liver fibrosis: a review.

Authors:  V Sánchez-Valle; N C Chávez-Tapia; M Uribe; N Méndez-Sánchez
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

6.  Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B.

Authors:  Ludger Leifeld; Silvia Cheng; Jan Ramakers; Franz-Ludwig Dumoulin; Christian Trautwein; Tilman Sauerbruch; Ulrich Spengler
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

7.  Serum YKL-40 is increased in patients with hepatic fibrosis.

Authors:  J S Johansen; P Christoffersen; S Møller; P A Price; J H Henriksen; C Garbarsch; F Bendtsen
Journal:  J Hepatol       Date:  2000-06       Impact factor: 25.083

Review 8.  Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications.

Authors:  Scott L Friedman
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2004-12

Review 9.  Ideal Experimental Rat Models for Liver Diseases.

Authors:  Sang Woo Lee; Sung Hoon Kim; Seon Ok Min; Kyung Sik Kim
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2011-05-31

10.  The Imbalance between Foxp3+Tregs and Th1/Th17/Th22 Cells in Patients with Newly Diagnosed Autoimmune Hepatitis.

Authors:  Ma Liang; Zhang Liwen; Zhuang Yun; Ding Yanbo; Chen Jianping
Journal:  J Immunol Res       Date:  2018-06-27       Impact factor: 4.818

View more
  1 in total

1.  High Dimensional Analyses of Circulating Immune Cells in Psoriatic Arthritis Detects Elevated Phosphorylated STAT3.

Authors:  Claudia Macaubas; Shamma S Rahman; Idit Lavi; Amir Haddad; Muna Elias; Deepanwita Sengupta; Devy Zisman; Elizabeth D Mellins
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.